NCT02370563终止1 期
An Open-Label Study of the Efficacy of 18F-FSPG PET/CT in Subjects With Intracranial Cancers
Life Molecular Imaging SA1 个研究点 分布在 1 个国家目标入组 26 人开始时间: 2014年11月最近更新:
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 发起方
- 入组人数
- 26
- 试验地点
- 1
- 主要终点
- Location and number of lesions and their location as detected by 18F-FSPG uptake above background in the brain of each study subject following visual inspection of the 18F-FSPG PET/CT scans
研究概览
简要总结
The aim of this study is to explore the efficacy of 18F-FSPG in the detection of primary or metastatic brain cancer lesions confirmed by a standard of truth, preferably histology. This is a single center, open labelled, non-randomized study. A total of 30 subjects with brain tumor or brain metastases will be enrolled. All different stages of malignancies will be recruited, including those with different types of pathologies and grades, and newly diagnosed or recurrent disease.
详细描述
Subjects with various types and grades of primary brain tumors or brain metastasis will be recruited. The brain tumor needs to be either histologically or clinically confirmed. 18F-FSPG will be injected intravenously into the subjects, and PET/CT imaging performed. Images will be assessed visually and quantitatively.
Available tumor specimens will be analyzed by immunohistochemistry (IHC) for example for expression of components of the system xc- and associated biomarkers.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Written informed consent
- •Participant must be able to complete a PET/CT scan and MRI without the use of sedation
- •Participant has
- •a primary brain tumor that has been histologically confirmed
- •OR confirmed or suspected recurrent brain cancer or brain metastasis for which the primary tumor has been histologically confirmed,
- •OR a brain lesion that is concerning for malignancy for which histopathological confirmation is anticipated following enrollment (e.g., biopsy or surgical resection of the tumor is scheduled)
- •OR a suspected low-grade brain tumor, where confirmation is based upon a combination of other imaging (e.g. PET/CT, MRI, diagnostic CT) and clinical assessment.
- •All pathology specimens must be within 1 year of the planned 18F-FSPG PET/CT scan.
- •The time interval between 18F-FSPG PET/CT and other imaging (including other PET/CTs, MRI or diagnostic CT) should be within 4 weeks (exceptions will be allowed for 6 weeks, if there are no other options)
- •Karnofsky Performance Status Scale of 60 or higher OR an ECOG Performance Status of 0-
- •No clinically relevant deviations in renal function (Serum Creatinine > Grade 2 CTCAE v4.0.). Maximal interval between confirmation and injection of 18F-FSPG is one week.
- •No chemotherapy, radiotherapy, or immune/biologic therapy scheduled or performed between other imaging (PET/CTs, MRI, or diagnostic CTs) and18F-FSPG PET/CT.
排除标准
- •Patient is scheduled for brain surgery and/or another invasive procedure within the time period of one month prior to 18F-FSPG administration. Minimally invasive needle biopsies are allowed.
- •Known hypersensitivity to the study drug or components of the preparation
- •Patient has completed participation in another clinical study involving administration of an investigational agent in the preceding 4 weeks. However, participation in clinical studies involving other investigational PET or SPECT tracers will not be excluded if in the opinion of the Investigator:
- •evaluation of 18F-FSPG safety and tolerability will not be confounded by the other investigational PET or SPECT tracer
- •a minimum of two days (or longer as necessary based on radiological half-life) have elapsed between investigational PET or SPECT tracer administrations to allow acceptable clearance of the tracer
- •the investigational PET or SPECT tracer administration was well tolerated by the patient.
- •Investigator precludes participation for scientific reasons, for reasons of compliance (e.g., concurrent disease which could compromise the subject's study completion), or for reasons of the patient's safety
研究组 & 干预措施
Arm 1
Experimental
18F-FSPG will be administered to 30 patients with brain tumors or brain metastases.
干预措施: 18F-FSPG (Drug)
结局指标
主要结局
Location and number of lesions and their location as detected by 18F-FSPG uptake above background in the brain of each study subject following visual inspection of the 18F-FSPG PET/CT scans
时间窗: 0-75 min
次要结局
- Location and number of lesions detected in the brain and whole body following visual inspection of the CT, MR or other available PET (e.g. 18F-FDG, 18F-FLT, etc.).(<4 weeks from FSPG PET/CT scan)
- Lesion size measured by means of ROIs drawn on (contrast-enhanced) MR or CT.(<4 weeks from FSPG PET/CT scan)
- Determination of FSPG PET/CT image quality based on visual inspection.(0-75 min)
- 18F-FSPG standardized uptake value (SUV) measured in each detected lesion and in the background (region without lesion).(0-75 min)
- Location and number of lesions detected in the whole body following visual inspection of the 18F-FSPG PET/CT scans(0-75 min)
- SUV measured in each detected lesion and in the background using other available PET tracers (e.g. 18F-FDG, 18F-FLT, etc.).(< 4 weeks from FSPG PET/CT scan)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
18F-FSPG PET/CT for Cancer Patients on TherapyB-Cell NeoplasmEstrogen Receptor NegativeHER2/Neu NegativeMetastatic Renal Cell CancerProgesterone Receptor NegativeStage III MesotheliomaStage III Renal Cell CancerStage IIIA Breast CancerStage IIIA Non-Small Cell Lung CancerStage IIIB Non-Small Cell Lung CancerStage IIIC Breast CancerStage IV Breast CancerStage IV MesotheliomaStage IV Non-Small Cell Lung CancerStage IV Renal Cell CancerTriple-Negative Breast CarcinomaNCT02599194Andrei Iagaru7
终止
不适用
18F-FSPG PET/CT as a Non-Invasive Imaging Biomarker for Treatment Response to Chemoradiation in Esophageal CancerEsophageal CarcinomaNCT06549413M.D. Anderson Cancer Center9
已完成
2 期
Diagnostic Validity of [18F]FSPG PET for the Assessment of Disease Activity in Inflammatory Bowel DiseaseInflammatory Bowel DiseasesUlcerative ColitisCrohn DiseaseNCT03546868Asan Foundation20
已完成
2 期
Diagnostic Validity of [18F]FSPG PET for the Assessment of Acute Rejection After Heart or Liver TransplantationGraft RejectionHeart TransplantationLiver TransplantationNCT04488094Asan Medical Center7
已完成
不适用
Clinical Study of 18F-FAPI-RGD in Ovarian CancerObservationalNCT06614062Sichuan Provincial People's Hospital30